Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Regains Compliance with Nasdaq Listing Requirements
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys received CE Mark approval for its FemHSG Catheter, expanding the company’s fertility diagnostics portfolio into the European market.
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed Complete
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Femasys launched FemaSeed Complete for OB/GYNs at the 2026 ACOG Annual Clinical and Scientific Meeting.